1. Home
  2. WD vs IMCR Comparison

WD vs IMCR Comparison

Compare WD & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Walker & Dunlop Inc

WD

Walker & Dunlop Inc

HOLD

Current Price

$49.92

Market Cap

1.7B

Sector

Finance

ML Signal

HOLD

Logo Immunocore Holdings plc

IMCR

Immunocore Holdings plc

HOLD

Current Price

$28.84

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WD
IMCR
Founded
1937
2008
Country
United States
United Kingdom
Employees
N/A
524
Industry
Finance: Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.5B
IPO Year
2010
2016

Fundamental Metrics

Financial Performance
Metric
WD
IMCR
Price
$49.92
$28.84
Analyst Decision
Strong Buy
Buy
Analyst Count
4
10
Target Price
$76.00
$66.33
AVG Volume (30 Days)
272.6K
314.6K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
5.34%
N/A
EPS Growth
N/A
30.39
EPS
0.46
0.25
Revenue
$1,234,306,000.00
$249,428,000.00
Revenue This Year
$20.60
$14.57
Revenue Next Year
$7.79
$8.21
P/E Ratio
$110.85
$115.42
Revenue Growth
8.99
43.05
52 Week Low
$42.12
$27.56
52 Week High
$90.00
$40.71

Technical Indicators

Market Signals
Indicator
WD
IMCR
Relative Strength Index (RSI) 46.15 46.58
Support Level $47.98 $27.69
Resistance Level $52.44 $31.56
Average True Range (ATR) 1.74 1.09
MACD -0.34 0.06
Stochastic Oscillator 30.90 42.56

Price Performance

Historical Comparison
WD
IMCR

About WD Walker & Dunlop Inc

Walker & Dunlop Inc is a United States-based commercial real estate finance company. It is principally engaged in originating, selling, and servicing a number of multifamily and other commercial real estate financing products that are sold under the programs of Freddie Mac, Fannie Mae, Ginnie Mae, and the Federal Housing Administration. The company is managed based on three reportable segments: Capital Markets (CM), Servicing & Asset Management (SAM), and Corporate. The company generates a majority of its total revenue from gains from mortgage banking activities and servicing fees. It conducts business solely in the United States.

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

Share on Social Networks: